Sight Sciences, Inc. SGHT
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +33.92%
- 1 year
- +53.25%
5D +0.66 (+6.49%)
- Market cap
- 590.25M
- Revenue (ttm)
- 79.54M
- Profit margin
- -63.30%
- EPS (ttm)
- -0.52
- Shares out
- 50.40M
- Forward P/E
- -4.33
- YTD return
- +33.92%
- 1-year return
- +53.25%
- 50-day average
- 4.47
- Volume
- 383.29K
- Avg volume
- 307.11K
- Open
- 10.60
- Previous close
- 10.77
- Day's range
- 10.31 – 10.88
- 52-week range
- 3.38 – 11.60
- Beta
- 2.73
- Analysts
- Hold
- Price target
- 5.02 (-52.7%)
Key statistics
- 200-day average
- 5.73
- Enterprise value
- 97.91M
- Price / sales
- 2.22
- Price / book
- 1.86
- Revenue growth
- 0.70%
- Free cash flow
- -10.15M
- Total cash
- 118.56M
- Total debt
- 35.28M
- Return on equity
- -45.36%
- Short % of float
- 2.67%
Fundamental scorecard
7 of 25 checks passed on SGHT’s reported financials
7of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.23 | -0.22 | +0.01 | +4.35% |
| Aug 1, 2024 | Jun 1, 2024 | -0.31 | -0.25 | +0.06 | +19.35% |
| Aug 1, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.29 | -0.33 | -0.04 | -13.79% |
| May 2, 2024 | Mar 1, 2024 | -0.29 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.35 | -0.22 | +0.13 | +37.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Citigroup | main | Neutral | Neutral |
| Dec 6, 2024 | UBS | init | — | Buy |
| Nov 11, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 8, 2024 | Piper Sandler | reit | Neutral | Neutral |
| Nov 8, 2024 | Needham | reit | — | Hold |
| Aug 21, 2024 | Lake Street | init | — | Buy |
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- sightsciences.com
News
Sight Sciences, Inc. (SGHT) is a Great Momentum Stock: Should You Buy? UBS Maintains Buy on Sight Sciences, Raises Price Target to $13.5
Piper Sandler Reiterates Overweight on Sight Sciences, Raises Price Target to $12
Sight Sciences Says Centers For Medicare & Medicaid Services Establishes New Direct Practice Expense Supply Code For Single-Use TearCare SmartLids Component Of TearCare System
Sight Sciences Q3 2026 Earnings Call Transcript Sight Sciences Raises FY2026 Sales Guidance from $88.000M-$92.000M to $92.000M-$93.000M vs $90.320M Est
Sight Sciences Q3 EPS $(0.12) Beats $(0.13) Estimate, Sales $24.923M Beat $23.512M Estimate
Your note
Sign in to keep a note on SGHT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BADAWI DAVID | Chief Technology Officer | Sale | Oct 1, 2024 | 1,756,480 |
| BADAWI PAUL | Chief Executive Officer | Sale | Oct 1, 2024 | 5,725,430 |
| BAUERLEIN ALISON | Chief Financial Officer | Sale | Sep 30, 2024 | 392,555 |
| ENCRANTZ STAFFAN | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 20, 2024 | 0 |
| HAYDEN JEREMY BRAGG | Officer | Sale | Sep 30, 2024 | 158,687 |
| LINK MATTHEW W | Officer | Sale | Oct 20, 2024 | 663,550 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 4.99% | 2,532,323 | 8.89M | Sep 29, 2024 |
| Blackrock Inc. | 4.41% | 2,235,777 | 7.85M | Sep 29, 2024 |
| Bank of America Corporation | 4.15% | 2,104,724 | 7.39M | Sep 29, 2024 |
| Vanguard Group Inc | 3.33% | 1,690,747 | 5.93M | Sep 29, 2024 |
| Jackson Square Partners, Llc | 1.81% | 918,059 | 3.22M | Sep 29, 2024 |
| Long Focus Capital Management, LLC | 1.70% | 865,097 | 3.04M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.84% | 933,753 | 3.28M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.70% | 861,864 | 3.03M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.91% | 459,335 | 1.61M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.71% | 360,805 | 1.27M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.60% | 304,775 | 1.07M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 179,036 | 628.42K | Oct 30, 2024 |
